Checkpoint Therapeutics, Inc. (CKPT) Financial Statements (2024 and earlier)

Company Profile

Business Address 95 SAWYER ROAD
WALTHAM, MA 02453
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments12,06854,73540,77226,07721,99519,225
Cash and cash equivalents12,06854,73540,77226,07721,99519,225
Other current assets731720261,532331
Other undisclosed current assets1,1499761,8048631,3721,857
Total current assets:13,29055,72842,59626,96624,89921,413
Noncurrent Assets
TOTAL ASSETS:13,29055,72842,59626,96624,89921,413
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:20,29724,9196,3677,25712,3175,762
Employee-related liabilities843535414439405
Accounts payable11,53516,1393,4383,0799,7503,645
Accrued liabilities1,473233385268377246
Other undisclosed accounts payable and accrued liabilities7,2897,7042,0093,4961,7511,466
Due to related parties1,3061,063850862776610
Other liabilities    3,496  
Other undisclosed current liabilities11,170  (3,496)  
Total current liabilities:32,77325,9827,2178,11913,0936,372
Noncurrent Liabilities
Total liabilities:32,77325,9827,2178,11913,0936,372
Equity
Equity, attributable to parent, including:(19,483)29,74635,37918,84711,80615,041
Common stock   6532
Common stock, value, subscriptions 1,8856,5984,6172,5101,7482,296
Additional paid in capital241,117223,001173,947136,442105,45171,772
Accumulated deficit(262,486)(199,862)(143,192)(120,111)(95,397)(59,030)
Other undisclosed equity, attributable to parent191111
Total equity:(19,483)29,74635,37918,84711,80615,041
TOTAL LIABILITIES AND EQUITY:13,29055,72842,59626,96624,89921,413

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues1922681,0691,7083,5061,725
Revenue, net1,725
Revenue from related parties1922681,0691,7083,506
Gross profit:1922681,0691,7083,5061,725
Operating expenses(58,525)(56,991)(24,270)(26,558)(40,246)(24,500)
Operating loss:(58,333)(56,723)(23,201)(24,850)(36,740)(22,775)
Nonoperating income (expense)(4,291)5312013637398
Investment income, nonoperating1605312013614898
Other nonoperating income     225 
Loss from continuing operations:(62,624)(56,670)(23,081)(24,714)(36,367)(22,677)
Loss before gain (loss) on sale of properties:(56,670)(23,081)(24,714)(36,367)(22,677)
Net loss available to common stockholders, diluted:(62,624)(56,670)(23,081)(24,714)(36,367)(22,677)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(62,624)(56,670)(23,081)(24,714)(36,367)(22,677)
Comprehensive loss, net of tax, attributable to parent:(62,624)(56,670)(23,081)(24,714)(36,367)(22,677)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: